A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer
| dc.contributor.advisor | Bowles, Harmony | en |
| dc.contributor.author | Gagliardo, Camille | |
| dc.contributor.author | Lybeck, Megan | |
| dc.contributor.author | Bowles, Harmony | |
| dc.date.accessioned | 2016-06-21T21:19:36Z | |
| dc.date.available | 2016-06-21T21:19:36Z | |
| dc.date.issued | 2016 | |
| dc.identifier.uri | http://hdl.handle.net/10150/613986 | |
| dc.description | Class of 2016 Abstract | en |
| dc.description.abstract | Objectives: To determine the number of patients treated with eribulin who required an alternate dosing schedule other than “day 1/day 8” due to side effects. Methods: Chart reviews were conducted on all patients who met inclusion criteria. Data collected included patient demographics, history of surgery/radiation, number of past chemotherapy treatments, and lab values prior to each eribulin cycle. Results: A total of 37 patients met inclusion criteria for this study. Ten patients were initially started on the “day 1/day 8” schedule and 3 of those patients required a change to the extended “day 1/day 15” schedule. The remaining 27 patients were started on the extended schedule. Conclusions: The number of patients requiring a dosing schedule change due to side effects was not statistically significant. This finding was due to the fact that the majority of patients were started on an alternate dosing schedule in the beginning of treatment. More extensive studies would be required to determine if a majority of patients would require this alternate dosing schedule, and if this should be initiated in all patients starting on eribulin. | |
| dc.language.iso | en_US | en |
| dc.publisher | The University of Arizona. | en |
| dc.rights | Copyright © is held by the author. | en |
| dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | |
| dc.subject | Retrospective Evaluation | en |
| dc.subject | Eribulin | en |
| dc.subject | Metastatic | en |
| dc.subject | Breast Cancer | en |
| dc.subject.mesh | Breast Neoplasms | |
| dc.subject.mesh | eribulin | |
| dc.subject.mesh | Drug Therapy | |
| dc.title | A Retrospective Evaluation of Eribulin Dosing Schedules in Metastatic Breast Cancer | en_US |
| dc.type | text | en |
| dc.type | Electronic Report | en |
| dc.contributor.department | College of Pharmacy, The University of Arizona | en |
| dc.description.collectioninformation | This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu. | en |
| html.description.abstract | Objectives: To determine the number of patients treated with eribulin who required an alternate dosing schedule other than “day 1/day 8” due to side effects. Methods: Chart reviews were conducted on all patients who met inclusion criteria. Data collected included patient demographics, history of surgery/radiation, number of past chemotherapy treatments, and lab values prior to each eribulin cycle. Results: A total of 37 patients met inclusion criteria for this study. Ten patients were initially started on the “day 1/day 8” schedule and 3 of those patients required a change to the extended “day 1/day 15” schedule. The remaining 27 patients were started on the extended schedule. Conclusions: The number of patients requiring a dosing schedule change due to side effects was not statistically significant. This finding was due to the fact that the majority of patients were started on an alternate dosing schedule in the beginning of treatment. More extensive studies would be required to determine if a majority of patients would require this alternate dosing schedule, and if this should be initiated in all patients starting on eribulin. |